ripekg:evaluation/RIPEA10E0E50BEC9CF233 |
prov:used |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA10E0E50BEC9CF233 |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA10E0E50BEC9CF233 |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripe:concerns |
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripe:recruitmentEndDate |
02-2024 |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripe:recruitmentEndDateExtractionRationale |
Setting: 'Seven hospitals in China between January 2022 and February 2024'; no specific day found. |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripe:recruitmentStartDate |
01-2022 |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripe:recruitmentStartDateExtractionRationale |
Setting: 'Seven hospitals in China between January 2022 and February 2024'; no specific day found. |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
ripe:studyEndDateExtractionRationale |
No explicit study completion date found. |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA10E0E50BEC9CF233-human-2-2 |
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA10E0E50BEC9CF233-inspectai-2-2 |